| The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019 KB Tran, JJ Lang, K Compton, R Xu, AR Acheson, HJ Henrikson, ... The Lancet 400 (10352), 563-591, 2022 | 662 | 2022 |
| Recent advances in the management of metastatic prostate cancer N Sayegh, U Swami, N Agarwal JCO Oncology Practice 18 (1), 45-55, 2022 | 115 | 2022 |
| Comparative effectiveness of immune checkpoint inhibitors vs chemotherapy by tumor mutational burden in metastatic castration-resistant prostate cancer RP Graf, V Fisher, J Weberpals, O Gjoerup, MB Tierno, RSP Huang, ... JAMA network Open 5 (3), e225394-e225394, 2022 | 69 | 2022 |
| Enhancing triage efficiency and accuracy in emergency rooms for patients with metastatic prostate cancer: a retrospective analysis of artificial intelligence-assisted triage … G Gebrael, KK Sahu, B Chigarira, N Tripathi, V Mathew Thomas, ... Cancers 15 (14), 3717, 2023 | 56 | 2023 |
| Treatment pattern and outcomes with systemic therapy in men with metastatic prostate cancer in the real-world patients in the United States U Swami, JA Sinnott, B Haaland, N Sayegh, TR McFarland, N Tripathi, ... Cancers 13 (19), 4951, 2021 | 45 | 2021 |
| SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer U Swami, RP Graf, RH Nussenzveig, V Fisher, H Tukachinsky, ... Clinical Cancer Research 28 (22), 4917-4925, 2022 | 42 | 2022 |
| & Agarwal, N.(2022) N Sayegh, U Swami Recent Advances in the Management of Metastatic Prostate Cancer. JCO …, 0 | 36 | |
| Advances in the treatment of metastatic prostate cancer G Gebrael, GG Fortuna, N Sayegh, U Swami, N Agarwal Trends in Cancer 9 (10), 840-854, 2023 | 29 | 2023 |
| Metastatic hormone-sensitive prostate cancer: toward an era of adaptive and personalized treatment AA Hamid, N Sayegh, B Tombal, M Hussain, CJ Sweeney, JN Graff, ... American Society of Clinical Oncology Educational Book 43, e390166, 2023 | 28 | 2023 |
| Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy J Graham, JC Wells, S Dudani, CL Gan, F Donskov, J Lee, ... European Journal of Cancer 171, 124-132, 2022 | 25 | 2022 |
| Seeing the forest for the trees—single-cell atlases link CD8+ T cells and macrophages to disease progression and treatment response in kidney cancer MY Koh, N Sayegh, N Agarwal Cancer Cell 39 (5), 594-596, 2021 | 25 | 2021 |
| Radium-223 plus enzalutamide versus enzalutamide in metastatic castration-refractory prostate cancer: final safety and efficacy results BL Maughan, A Kessel, TR McFarland, N Sayegh, R Nussenzveig, ... The Oncologist 26 (12), 1006-e2129, 2021 | 24 | 2021 |
| The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer N Agarwal, T Zhang, E Efstathiou, N Sayegh, A Engelsberg, F Saad, ... European Journal of Cancer 192, 113249, 2023 | 20 | 2023 |
| Cardiovascular toxicities associated with tyrosine kinase inhibitors N Sayegh, J Yirerong, N Agarwal, D Addison, M Fradley, J Cortes, ... Current cardiology reports 25 (4), 269-280, 2023 | 18 | 2023 |
| Women's sexual function before and during COVID‐19 pandemic: A systematic review and meta‐analysis K Hessami, N Sayegh, AS Abdolmaleki, S Bakht, S Qaderi, M Darabi, ... Journal of Obstetrics and Gynaecology Research 48 (9), 2285-2295, 2022 | 17 | 2022 |
| Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy … G Gebrael, N Sayegh, VM Thomas, B Chigarira, N Tripathi, YJ Jo, H Li, ... Prostate Cancer and Prostatic Diseases 27 (2), 279-282, 2024 | 12 | 2024 |
| Association between time-of-day of immune checkpoint blockade administration and outcomes in metastatic renal cell carcinoma N Dizman, A Govindarajan, ZB Zengin, L Meza, N Tripathi, N Sayegh, ... Clinical Genitourinary Cancer 21 (5), 530-536, 2023 | 12 | 2023 |
| Body composition and metastatic prostate cancer survivorship AM Coletta, N Sayegh, N Agarwal Cancer treatment and research communications 27, 100322, 2021 | 12 | 2021 |
| Treatment patterns and attrition with lines of therapy for advanced urothelial carcinoma in the US VM Thomas, Y Jo, N Tripathi, S Roy, B Chigarira, A Narang, G Gebrael, ... JAMA Network Open 7 (5), e249417-e249417, 2024 | 11 | 2024 |
| Clinical evidence and selecting patients for treatment with erdafitinib in advanced urothelial carcinoma N Sayegh, N Tripathi, N Agarwal, U Swami OncoTargets and Therapy 15, 1047, 2022 | 11 | 2022 |
NEERAJ Agarwaluniversity of utahEmail được xác minh tại hci.utah.edu
